A statement released earlier today by Maxim Group about BeiGene (NASDAQ:BGNE) bumps the target price to $41.00
- Updated: September 21, 2016
In a report released on 09/22/2016 Maxim Group increased the stock price target of BeiGene (NASDAQ:BGNE) to $41.00 reporting a possible upside of 0.32%.
Just yesterday BeiGene (NASDAQ:BGNE) traded 0.00% even at $30.98. BeiGene’s 50-day moving average is $29.30 and its 200-day moving average is $28.99. The last closing price is up 6.88% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 62,927 shares of BGNE traded hands, up from an average trading volume of 54,806
Recent Performance Chart
BeiGene has 52 week low of $22.51 and a 52 week high of $35.60 and has a market capitalization of $0.
Brief Synopsis On BeiGene (NASDAQ:BGNE)
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton's tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.